# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Capricor Therapeutics announced successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA).
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results--
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the on...
--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP...
Oppenheimer analyst Leland Gershell initiates coverage on Capricor Therapeutics (NASDAQ:CAPR) with a Outperform rating and a...
Ladenburg Thalmann analyst Aydin Huseynov maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price targ...
Cantor Fitzgerald analyst Kristen Kluska reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Overweight and maintains $8 p...